Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA.
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Suite 3030, Boston, MA 02120, USA.
Drug Discov Today. 2021 Jan;26(1):273-281. doi: 10.1016/j.drudis.2020.09.024. Epub 2020 Oct 1.
The approval of sofosbuvir (Sovaldi) in 2013 transformed chronic hepatitis C virus (HCV) care, but its high cost was criticized in part because of reports of substantial public involvement in its development. We developed a methodology to assess the public's contribution through the National Institutes of Health (NIH) in developing sofosbuvir. Using key terms from the timeline of sofosbuvir, we identified articles in PubMed; linked them to federal funding using the NIH RePORTER; reviewed the title, organization, and investigator of each resulting award for relatedness; and converted related awards to 2018 US dollars. Of 6043 unique awards, we identified 29 that were directly (US$7.7 million) and 110 that were indirectly (US$53.2 million) related awards made to major academic institutions and companies engaged in the development of the drug. These findings indicate that public funding had a key role in developing sofosbuvir, with an estimated US$60.9 million provided in NIH funding.
2013 年索非布韦（Sovaldi）的批准改变了慢性丙型肝炎病毒（HCV）的治疗方式，但由于有报道称公众在其研发过程中发挥了重要作用，其高昂的成本受到了部分批评。我们开发了一种通过美国国立卫生研究院（NIH）评估索非布韦研发过程中公众贡献的方法。我们使用了索非布韦时间表中的关键术语，在 PubMed 中识别出相关文章；通过 NIH RePORTER 将它们与联邦资金联系起来；根据相关性，对每个相关奖励的标题、组织和研究者进行了审查；并将相关奖励转换为 2018 年的美元。在 6043 个独特的奖励中，我们确定了 29 个直接（770 万美元）和 110 个间接（5320 万美元）与主要学术机构和参与药物开发的公司相关的奖励。这些发现表明，公共资金在索非布韦的研发中发挥了关键作用，NIH 提供了约 6090 万美元的资金。
